Ulcerative colitis is a chronic inflammatory bowel disease that affects the colon and rectum. It is characterized by inflammation and ulcers in the lining of the colon, which can cause a range of symptoms, including diarrhea, abdominal pain, rectal bleeding, and fatigue. The exact cause of ulcerative colitis is not known, but it is believed to be an autoimmune disorder, in which the immune system mistakenly attacks the cells of the colon.

According to a report by Stratview Research, the ulcerative colitis market was estimated at US$ 6.6 billion in 2021 and is expected to grow at a CAGR of 5.8% during 2022-2028 to reach US$ ~10.9 billion in 2028.

Ulcerative colitis can be a debilitating disease that affects a person's quality of life. The severity and duration of symptoms can vary widely from person to person, and some may experience long periods of remission between flare-ups. Treatment for ulcerative colitis typically involves a combination of medications to control inflammation and manage symptoms, as well as lifestyle modifications and surgery in some cases.

The prevalence of ulcerative colitis varies by region, with the highest rates reported in North America and Europe. The disease can affect people of any age, but it is most commonly diagnosed in young adults between the ages of 15 and 30. While there is no cure for ulcerative colitis, ongoing research is focused on developing new and more effective treatments to improve the lives of those affected by the disease.

The market is divided based on disease type, molecule type, and route of administration. On the basis of disease type, the market is further segmented into mild, moderate, and severe. The moderate segment is expected to grow highest over the anticipated period.

Based on molecule type, the ulcerative colitis market has been divided into biologics and small molecules. The biologcs segment is expected to hold the major share owing to the high awareness.

The ulcerative colitis market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2021, North America is anticipated to be the ulcerative colitis market's largest region. Due to improved healthcare costs, more public understanding and awareness, and technological innovation in the US, this country dominates the ulcerative colitis market. However, the UK is anticipated to grow more quickly and with a high CAGR in the ulcerative colitis drug market due to improvements in healthcare access and quality, a rise in disease management knowledge, and rising healthcare spending in this area. The popularity of biosimilars in developing nations like China and Japan may change the therapeutic environment here.

Key Players

The market for ulcerative colitis is highly competitive. The state of the economy and government assistance have a direct impact on the expansion of the businesses. Based on their product's quality and market penetration in both the target and growing markets, these companies distinguish their ulcerative colitis driver in the industry. Furthermore, recent important mergers and acquisitions in the sector have had a big impact on the dynamics of competition. For instance:

• In 2022, the US FDA approved small molecules, namely, Jyseleca (Filgotinib) and Rinvoq (Upadacitinib) to treat moderate to severe cases of ulcerative colitis.
• In October 2022, The National Institute for Health and Care Excellence (NICE) has recommended Bristol Myers Squibb's (BMS) Zeposia (ozanimod) for the treatment of adults with moderate-to-severe active ulcerative colitis (UC). This is the first time that NICE has recommended an oral sphingosine 1-phosphate (S1P) receptor modulator for the treatment of UC. The advice is specifically for individuals whose conditions have not responded well to earlier biologic therapy or conventional therapy, or who are intolerant of it.
• In July 2021, Bristol Myers Squibb reported that neither the primary efficacy endpoint of clinical remission at Week 12 nor the secondary efficacy endpoints were met in the Phase 2 LATTICE-UC study comparing deucravacitinib, a first-in-class oral selective tyrosine kinase 2 (TYK2) inhibitor, to placebo in patients with moderate to severe ulcerative colitis (UC). Deucravacitinib's safety profile was similar with trials on psoriasis and psoriatic arthritis that have already been published, and no new safety signals were noticed.

The overall competitive landscape has been affected due to these mergers and acquisitions. The following are the major players in the ulcerative colitis market:

• AbbVie Inc
• Bristol-Myers Squibb
• CellTrion
• EA Pharma
• Eli Lilly and Company
• InDex
• Johnson & Johnson
• Pfizer Inc 
• Reistone Biopharma Co. Ltd.
• Takeda Pharmaceutical Co Ltd.

Request a sample:

https://www.stratviewresearch.com/Request-Sample/3082/ulcerative-colitis-market.html#form

The Ulcerative Colitis Market is a complex and rapidly evolving landscape, driven by an increasing prevalence of the disease, advances in technology and research, and a growing demand for effective and personalized treatments. While there are several established treatment options available, including anti-inflammatory drugs, immune system suppressors, and biologics, there is a need for new and innovative treatments that can provide better outcomes for patients.

The market is highly competitive, with several major pharmaceutical companies developing and marketing treatments for the disease. However, the high cost of some treatments may be a barrier to access for some patients. Further research is needed to develop more effective and affordable treatments, as well as to better understand the underlying mechanisms of the disease.

Key takeaways from the Ulcerative Colitis Market include:

• Ulcerative colitis is a chronic inflammatory bowel disease that affects the colon and rectum.
• The market is driven by an increasing prevalence of the disease, a growing aging population, and a demand for effective and personalized treatments.
• Current treatment options include anti-inflammatory drugs, immune system suppressors, and biologics.
• Several promising new treatments are in the pipeline, including small molecules and biologics that target specific pathways and mechanisms involved in the disease.
• The market is highly competitive, with several major pharmaceutical companies developing and marketing treatments for the disease.
• The high cost of some treatments may be a barrier to access for some patients.
• Further research is needed to develop more effective and affordable treatments, as well as to better understand the underlying mechanisms of the disease.

Research Methodology

This report offers high-quality insights and is the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact book, press release, journals, investor presentation, white papers, patents, and articles have been leveraged to gather the data. We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both the qualitative and quantitative insights.